The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
about
Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusionReappraising the timing of transplant for indolent non-Hodgkin lymphomas.Treatment with campath-1H for relapsed chronic lymphocytic leukemia after allogeneic peripheral blood stem cell transplantation does not abrogate the development of chronic GVHD.Escalating doses of donor lymphocytes for incipient graft rejection following SCT for thalassemia.Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisitedNCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioMyeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease.Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation FailurePostnatal donor lymphocytes enhance prenatally-created chimerism at the risk of graft-versus-host disease.The role of allogeneic transplantation in non-Hodgkin's lymphoma.Personalized medical treatment strategies for patients with chronic myeloid leukemia.The graft-versus-lymphoma effect: clinical review and future opportunities.Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: 'what is the best recipe?'.Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.The fate of human Langerhans cells in hematopoietic stem cell transplantationIdentification of a radio-resistant and cycling dermal dendritic cell population in mice and men.Dendritic cells in allogeneic hematopoietic stem cell transplantation.Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents.Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct.Optimization of allogeneic transplant conditioning: not the time for dogma.Cellular therapy following allogeneic stem-cell transplantation.Targets and strategies for T-cell based vaccines in patients with B-cell chronic lymphocytic leukemia.Viewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning--is there still an upper age limit? A focus on myeloid neoplasia.Graft-versus-host disease after donor leukocyte infusions: presentation and management.Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation.Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab eraDifferential rates of replacement of human dermal dendritic cells and macrophages during hematopoietic stem cell transplantation.Acute GvHD: pathogenesis and classification.Donor lymphocyte infusions: the long and winding road: how should it be traveled?Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation.In pursuit of the allo-immune response in multiple myeloma: where do we go from here?Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.Treatment of lymphoma with adoptively transferred T cells.Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation.The allogeneic graft-versus-cancer effect.NKT cells, Treg, and their interactions in bone marrow transplantation.Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation.Future perspectives: should Th17 cells be considered as a possible therapeutic target in acute myeloid leukemia patients receiving allogeneic stem cell transplantation?
P2860
Q28296706-2957A384-B8AF-45BB-81AE-D197F6B6603BQ30248407-B4804C21-1EFD-4498-A23A-00CD06A75078Q33198259-A5DB0F8E-665A-4A4D-811D-DC9EECD2A669Q33386915-9CC200A9-023F-4268-998A-8323E790B660Q33770125-48C12F66-07EC-43D8-9128-A0880E0BFA0DQ34065058-7E30F04D-F3A6-418B-8F5D-9BFD42E5AF67Q34202277-8E0B9B07-E66E-400A-AAC6-B0E20EB19FC4Q34449575-0BD7092A-350F-43B6-81D3-EED395503808Q35563832-317F7019-A6DA-4D1A-B5DF-E59474252121Q35826497-0A22F9FC-534F-4B17-8E2E-814DBBC008BCQ36003103-EEA31277-F927-43E6-B24D-A7F10A18CBE8Q36118424-53675E6E-D598-4C8A-A332-A6E3C45BB065Q36128232-35ADFBE8-BAB8-4D4B-BA48-BF2C46664CF5Q36182976-FA1F07FF-0BFC-4013-A1C9-9692C302FC2FQ36219690-06806E83-608C-42C2-8556-B28F7B425213Q36227929-7056AF01-67D3-43D5-98AF-A4330E003D77Q36228168-DA719C27-A341-4E22-9D48-0EA9DDFC38C0Q36272587-05A57DA3-19E3-491D-BFC5-49F7521F852DQ36548362-B9E7970B-8C1B-44E8-80BA-BE8638DE66B6Q36548370-44464D0E-4E5A-42C9-BBBB-AA2FBD60AB23Q36556498-FC1A36A8-6117-4EE7-BDF5-3C60DAF95451Q36612643-5BC20203-EDF8-446E-B675-1619BBA1C083Q36637647-338401A5-9478-46C6-A044-0EF4AC2D9C2AQ36824553-AF7FA010-905D-42AD-B85A-1D6BBA843664Q36825001-A6E01801-DC9F-43A1-9A73-BE4974B9E782Q37008223-A4DA956F-EB9C-4119-B801-3BBCA10FABF4Q37061964-50E085CF-137A-4681-90FC-F6874CEB4291Q37071972-452EEB5C-02AE-46BA-AAF2-05F88463B3B0Q37106747-6BB20A3B-AD90-4430-9421-11C7D741771BQ37188484-D70A8870-EE42-4312-BE13-352D704EAB8EQ37246638-41A86A8F-921E-4C3E-9BC5-E56BBD82F5C4Q37321812-023EC781-BCBF-4048-BBFC-A191461428D5Q37349835-0C441BA5-C460-4BE8-85E4-E1F9FBC874BCQ37354362-8F603D18-482C-44A7-B2DC-E9760E2D175EQ37419728-04F62AE6-D746-4213-B2AA-25E054F499FDQ37445265-356C5B24-5669-4C71-B2EE-7435CBF53A60Q37593125-0AA68028-86B3-431E-9645-A49CDB6CFDB8Q37768104-722192C9-A361-408D-B917-612C69BEBE29Q37832506-85D976FF-52E3-4264-9C50-0B5921DDB20FQ37944472-1CABE01E-E1F0-427A-9688-EE81A17874D7
P2860
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
The toxicity and efficacy of d ...... eic stem cell transplantation.
@en
The toxicity and efficacy of d ...... eic stem cell transplantation.
@nl
type
label
The toxicity and efficacy of d ...... eic stem cell transplantation.
@en
The toxicity and efficacy of d ...... eic stem cell transplantation.
@nl
prefLabel
The toxicity and efficacy of d ...... eic stem cell transplantation.
@en
The toxicity and efficacy of d ...... eic stem cell transplantation.
@nl
P2093
P1433
P1476
The toxicity and efficacy of d ...... eic stem cell transplantation.
@en
P2093
Andrew Davies
Ann Hunter
Catherine D Williams
David I Marks
Dominic Culligan
Donald W Milligan
Fiona J Clark
Graeme M Smith
Jamie Cavenagh
P304
P356
10.1182/BLOOD-2002-02-0506
P407
P577
2002-11-01T00:00:00Z